Investments
101Portfolio Exits
36Funds
1About HBM Partners
HBM BioCapital (EUR) L.P. and HBM BioCapital (USD) L.P. are private equity funds with a total committed capital of EUR 115 million. The funds are managed by HBM Partners and are focused on healthcare / life science investments in Europe and the U.S. They were launched in 2005. HBM BioCapital I has made investments in 15 private companies in the pharma, biotechnology, medical devices and diagnostics industries, seven of which have been sold or listed on a stock exchange. Larger transactions were shared with HBM BioVentures. Investors in HBM BioCapital I are HBM BioVentures, larger institutional investors and pharma entrepreneurs.
Want to inform investors similar to HBM Partners about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest HBM Partners News
Jan 30, 2023
30-Jan-2023 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Dr Andreas Wicki, Chief Executive Officer of HBM Healthcare Investments, will be taking a brief leave of absence to adress a treatable health matter. Dr Wicki will remain involved to the extent practicable. In the interim, Hans Peter Hasler, Chairman of the Board of Directors, will be responsible for the management of HBM Healthcare Investments as Executive Chairman, together with CFO Erwin Troxler. They will be actively supported by Dr Matthias Fehr and Dr Ivo Staijen, who have been leading the investment teams for private equity and public equity at the investment advisor HBM Partners for several years. The Board of Directors and the employees of HBM Healthcare Investments and HBM Partners wish Andreas Wicki a speedy recovery. Contact
HBM Partners Investments
101 Investments
HBM Partners has made 101 investments. Their latest investment was in Neuron23 as part of their Series C on March 3, 2022.
HBM Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
3/30/2022 | Series C | Neuron23 | $100M | No | 2 | |
12/29/2021 | Series G | Gynesonics | $32.5M | No | ||
5/20/2021 | Series C | Numab Therapeutics | $111M | Yes | 6 | |
3/8/2021 | Series D | |||||
1/11/2021 | Series E |
Date | 3/30/2022 | 12/29/2021 | 5/20/2021 | 3/8/2021 | 1/11/2021 |
|---|---|---|---|---|---|
Round | Series C | Series G | Series C | Series D | Series E |
Company | Neuron23 | Gynesonics | Numab Therapeutics | ||
Amount | $100M | $32.5M | $111M | ||
New? | No | No | Yes | ||
Co-Investors | |||||
Sources | 2 | 6 |
HBM Partners Portfolio Exits
36 Portfolio Exits
HBM Partners has 36 portfolio exits. Their latest portfolio exit was Arena Pharmaceuticals on December 13, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/13/2021 | Acq - P2P | 5 | |||
6/29/2021 | Acquired | 2 | |||
7/24/2020 | IPO | Public | 7 | ||
Date | 12/13/2021 | 6/29/2021 | 7/24/2020 | ||
|---|---|---|---|---|---|
Exit | Acq - P2P | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 5 | 2 | 7 |
HBM Partners Fund History
1 Fund History
HBM Partners has 1 fund, including HBM Cobra India.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
3/5/2020 | HBM Cobra India | $48.86M | 1 |
Closing Date | 3/5/2020 |
|---|---|
Fund | HBM Cobra India |
Fund Type | |
Status | |
Amount | $48.86M |
Sources | 1 |
HBM Partners Team
3 Team Members
HBM Partners has 3 team members, including current Chief Executive Officer, Andreas Wicki.
Name | Work History | Title | Status |
|---|---|---|---|
Andreas Wicki | Chief Executive Officer | Current | |
Name | Andreas Wicki | ||
|---|---|---|---|
Work History | |||
Title | Chief Executive Officer | ||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.